RT @urojmayor: Interesante. Personalizando el bloqueo hormonal? https://t.co/1EG6ulo8ZS
Interesante. Personalizando el bloqueo hormonal?
RT @DGlaucomflecken: (Twitter self help seminar) Me: (rubbing temples) Ok let's go over this one more time. What is your twitter handle?…
RT @DGlaucomflecken: (Twitter self help seminar) Me: (rubbing temples) Ok let's go over this one more time. What is your twitter handle?…
RT @DGlaucomflecken: (Twitter self help seminar) Me: (rubbing temples) Ok let's go over this one more time. What is your twitter handle?…
RT @DGlaucomflecken: (Twitter self help seminar) Me: (rubbing temples) Ok let's go over this one more time. What is your twitter handle?…
RT @DGlaucomflecken: (Twitter self help seminar) Me: (rubbing temples) Ok let's go over this one more time. What is your twitter handle?…
RT @DGlaucomflecken: (Twitter self help seminar) Me: (rubbing temples) Ok let's go over this one more time. What is your twitter handle?…
RT @DGlaucomflecken: (Twitter self help seminar) Me: (rubbing temples) Ok let's go over this one more time. What is your twitter handle?…
RT @DGlaucomflecken: (Twitter self help seminar) Me: (rubbing temples) Ok let's go over this one more time. What is your twitter handle?…
🤔
RT @DGlaucomflecken: (Twitter self help seminar) Me: (rubbing temples) Ok let's go over this one more time. What is your twitter handle?…
RT @DGlaucomflecken: (Twitter self help seminar) Me: (rubbing temples) Ok let's go over this one more time. What is your twitter handle?…
(Twitter self help seminar) Me: (rubbing temples) Ok let's go over this one more time. What is your twitter handle? JAMAOphth: @JAMAOphth Me: Great and what kind of tweets do you do? JAMAOphth: Ophthalmology tweets Me: That's right. Ok, now try sendin
RT @OptiProstate: At today's lab meeting, Omri took us through a great paper by Feng et al which used the breast cancer classifier PAM50 in…
At today's lab meeting, Omri took us through a great paper by Feng et al which used the breast cancer classifier PAM50 in a PCa cohort, and reclassified the tumours into luminal and basal subtypes, representing a new approach in treatment selection 🔬 http
RT @avrasyauroonko: Prostat kanserinin luminal ve bazal tipleri farklı klinik davranış gösteriyorlar. Görünen o ki, luminal tümörlerde andr…
RT @JAMAOnc: Luminal/basal subtyping of #ProstateCancer is prognostic for clin outcomes & predictive of post-op benefit of ADT. https://t.c…
RT @JAMAOnc: Luminal/basal subtyping of #ProstateCancer is prognostic for clin outcomes & predictive of post-op benefit of ADT. https://t.c…
RT @JAMAOnc: Luminal/basal subtyping of #ProstateCancer is prognostic for clin outcomes & predictive of post-op benefit of ADT. https://t.c…
RT @JAMAOnc: Luminal/basal subtyping of #ProstateCancer is prognostic for clin outcomes & predictive of post-op benefit of ADT. https://t.c…
RT @JAMAOnc: Luminal/basal subtyping of #ProstateCancer is prognostic for clin outcomes & predictive of post-op benefit of ADT. https://t.c…
Luminal/basal subtyping of #ProstateCancer is prognostic for clin outcomes & predictive of post-op benefit of ADT. https://t.co/jLFWzrX1P7 #PCSM
RT @avrasyauroonko: Prostat kanserinin luminal ve bazal tipleri farklı klinik davranış gösteriyorlar. Görünen o ki, luminal tümörlerde andr…
RT @avrasyauroonko: Prostat kanserinin luminal ve bazal tipleri farklı klinik davranış gösteriyorlar. Görünen o ki, luminal tümörlerde andr…
RT @avrasyauroonko: Prostat kanserinin luminal ve bazal tipleri farklı klinik davranış gösteriyorlar. Görünen o ki, luminal tümörlerde andr…
RT @avrasyauroonko: Prostat kanserinin luminal ve bazal tipleri farklı klinik davranış gösteriyorlar. Görünen o ki, luminal tümörlerde andr…
Prostat kanserinin luminal ve bazal tipleri farklı klinik davranış gösteriyorlar. Görünen o ki, luminal tümörlerde androjen sinyalizasyonu artmış ve daha progresifler ,diğer yandan postop ADT'ye daha iyi yanıt veriyorlar. https://t.co/wuY4RSIE4i https://t
RT @JAMAOnc: Luminal and Basal Subtyping of Prostate Cancer https://t.co/9Qs3erqGEJ
RT @JAMAOnc: Luminal and Basal Subtyping of Prostate Cancer https://t.co/9Qs3erqGEJ
RT @JAMAOnc: Luminal and Basal Subtyping of Prostate Cancer https://t.co/9Qs3erqGEJ
Luminal and Basal Subtyping of Prostate Cancer https://t.co/9Qs3erqGEJ
RT @PCF_Science: PCF study demonstrates that molecular subtyping of #ProstateCancer into luminal & basal status w/ the PAM50 classifier is…
RT @PCF_Science: PCF study demonstrates that molecular subtyping of #ProstateCancer into luminal & basal status w/ the PAM50 classifier is…
RT @PCF_Science: PCF study demonstrates that molecular subtyping of #ProstateCancer into luminal & basal status w/ the PAM50 classifier is…
@felixfengmd @DrSpratticus @DrPaulNguyen @PCFnews @EricKleinMD @dr_coops @WonKimMD @charlesryanmd @CedarsUroOncol @Howie2241 @Davicioni @ashleyrossmdphd @EdwardSchaeffer PCF study "Associations of Luminal and Basal Subtyping of Prostate Cancer With Progno
RT @PCF_Science: PCF study demonstrates that molecular subtyping of #ProstateCancer into luminal & basal status w/ the PAM50 classifier is…
RT @PCF_Science: PCF study demonstrates that molecular subtyping of #ProstateCancer into luminal & basal status w/ the PAM50 classifier is…
Luminal and Basal Subtyping of Prostate Cancer https://t.co/4qTn9hHAzL https://t.co/rXIDwb4693
RT @PCF_Science: PCF study demonstrates that molecular subtyping of #ProstateCancer into luminal & basal status w/ the PAM50 classifier is…
RT @SoaresAndrey: Another very important data about prostate cancer biology https://t.co/l1xXAtULRO
RT @PCF_Science: PCF study demonstrates that molecular subtyping of #ProstateCancer into luminal & basal status w/ the PAM50 classifier is…
RT @PCF_Science: PCF study demonstrates that molecular subtyping of #ProstateCancer into luminal & basal status w/ the PAM50 classifier is…
RT @PCF_Science: PCF study demonstrates that molecular subtyping of #ProstateCancer into luminal & basal status w/ the PAM50 classifier is…
RT @PCF_Science: PCF study demonstrates that molecular subtyping of #ProstateCancer into luminal & basal status w/ the PAM50 classifier is…
RT @PCF_Science: PCF study demonstrates that molecular subtyping of #ProstateCancer into luminal & basal status w/ the PAM50 classifier is…
RT @PCF_Science: PCF study demonstrates that molecular subtyping of #ProstateCancer into luminal & basal status w/ the PAM50 classifier is…
RT @PCF_Science: PCF study demonstrates that molecular subtyping of #ProstateCancer into luminal & basal status w/ the PAM50 classifier is…
RT @PCF_Science: PCF study demonstrates that molecular subtyping of #ProstateCancer into luminal & basal status w/ the PAM50 classifier is…
RT @PCF_Science: PCF study demonstrates that molecular subtyping of #ProstateCancer into luminal & basal status w/ the PAM50 classifier is…
RT @PCF_Science: PCF study demonstrates that molecular subtyping of #ProstateCancer into luminal & basal status w/ the PAM50 classifier is…
RT @PCF_Science: PCF study demonstrates that molecular subtyping of #ProstateCancer into luminal & basal status w/ the PAM50 classifier is…
RT @SoaresAndrey: Another very important data about prostate cancer biology https://t.co/l1xXAtULRO
RT @PCF_Science: PCF study demonstrates that molecular subtyping of #ProstateCancer into luminal & basal status w/ the PAM50 classifier is…
RT @PCF_Science: PCF study demonstrates that molecular subtyping of #ProstateCancer into luminal & basal status w/ the PAM50 classifier is…
RT @PCF_Science: PCF study demonstrates that molecular subtyping of #ProstateCancer into luminal & basal status w/ the PAM50 classifier is…
RT @PCF_Science: PCF study demonstrates that molecular subtyping of #ProstateCancer into luminal & basal status w/ the PAM50 classifier is…
RT @PCF_Science: PCF study demonstrates that molecular subtyping of #ProstateCancer into luminal & basal status w/ the PAM50 classifier is…
RT @PCF_Science: PCF study demonstrates that molecular subtyping of #ProstateCancer into luminal & basal status w/ the PAM50 classifier is…
RT @PCF_Science: PCF study demonstrates that molecular subtyping of #ProstateCancer into luminal & basal status w/ the PAM50 classifier is…
RT @SoaresAndrey: Another very important data about prostate cancer biology https://t.co/l1xXAtULRO
RT @PCF_Science: PCF study demonstrates that molecular subtyping of #ProstateCancer into luminal & basal status w/ the PAM50 classifier is…
RT @PCF_Science: PCF study demonstrates that molecular subtyping of #ProstateCancer into luminal & basal status w/ the PAM50 classifier is…
RT @PCF_Science: PCF study demonstrates that molecular subtyping of #ProstateCancer into luminal & basal status w/ the PAM50 classifier is…
RT @PCF_Science: PCF study demonstrates that molecular subtyping of #ProstateCancer into luminal & basal status w/ the PAM50 classifier is…
Another very important data about prostate cancer biology https://t.co/l1xXAtULRO
RT @PCF_Science: PCF study demonstrates that molecular subtyping of #ProstateCancer into luminal & basal status w/ the PAM50 classifier is…
RT @PCF_Science: PCF study demonstrates that molecular subtyping of #ProstateCancer into luminal & basal status w/ the PAM50 classifier is…
RT @PCF_Science: PCF study demonstrates that molecular subtyping of #ProstateCancer into luminal & basal status w/ the PAM50 classifier is…
PCF study demonstrates that molecular subtyping of #ProstateCancer into luminal & basal status w/ the PAM50 classifier is prognostic for clinical outcomes and may be associated w/ response to ADT. @felixfengmd @DrSpratticus @DrPaulNguyen et al. @PCFnew
RT @NatRevClinOncol: In prostate cancer, luminal A/B & basal molecular subtypes predict prognosis & maybe response to postoperative ADT: ht…
RT @NatRevClinOncol: In prostate cancer, luminal A/B & basal molecular subtypes predict prognosis & maybe response to postoperative ADT: ht…
RT @NatRevClinOncol: In prostate cancer, luminal A/B & basal molecular subtypes predict prognosis & maybe response to postoperative ADT: ht…
RT @aftimosp: Associations of Luminal and Basal Subtyping of Prostate Cancer With Prognosis and Response to ADT https://t.co/7MFAdifNok
Associations of Luminal and Basal Subtyping of Prostate Cancer With Prognosis and Response to ADT https://t.co/7MFAdifNok
Luminal and Basal Subtyping of Prostate #pcsm https://t.co/mH17QYebwP
Molecular subtyping comes to prostate cancers - https://t.co/ETG4VQZKEK
Luminal and Basal Subtyping of Prostate Cancer https://t.co/ny41zrtlaj
RT @pgrnhub: Novel insight for predicting prostate cancer patients who may benefit from ADT - Luminal B tumors response better https://t.co…
Novel insight for predicting prostate cancer patients who may benefit from ADT - Luminal B tumors response better https://t.co/PY2oJcBKTW